GlassScriptPhysician profile
May Abdo-Matkiwsky
NPI 1306887708
$5,996.85
in general payments reported to CMS, 2019-2025
57 companies · $521 in 2025
The $521 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $539 · 2021: $433 · 2022: $742 · 2023: $552 · 2024: $1,732 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,340 · Food and Beverage: $1,320 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,340.00 |
| Food and Beverage | $1,320.41 |
| Education | $144.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,570.51 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Pfizer INC. | $554.40 | 2019-2025 | |
| Janssen Biotech, INC. | $476.14 | 2019-2025 | Erleada, Akeega, Balversa |
| Novartis Pharmaceuticals Corporation | $439.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $325.97 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $297.08 | 2019-2025 | Padcev, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $291.01 | 2019-2025 | Opdivo, Opdualag |
| Amgen INC. | $206.91 | 2019-2023 | Lumakras |
| Lilly USA, LLC | $148.75 | 2019-2023 | Verzenio, Retevmo, Jaypirca |
| Genentech USA, INC. | $145.12 | 2019-2024 | Venclexta, Alecensa, Tecentriq |
| Glaxosmithkline, LLC. | $137.06 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $104.32 | 2019-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $60.48 | 2020-2025 | Ultomiris |
| Incyte Corporation | $59.78 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.13 | 2019-2021 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Abdo-Matkiwsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.